Literature DB >> 15300155

Chronotherapy of hypertension.

Ramón C Hermida1, Michael H Smolensky.   

Abstract

PURPOSE OF REVIEW: Blood pressure displays appreciable predictable-in-time circadian variation. The chronotherapy of hypertension takes into account the clinically relevant features of the 24-h pattern of blood pressure, e.g. the accelerated morning rise and nighttime decline during sleep, plus potential administration circadian time determinants of the pharmacokinetics and dynamics of antihypertensive medications. RECENT
FINDINGS: Significant administration-time differences in the kinetics (i.e. chronokinetics) plus the beneficial and adverse effects (termed chronodynamics) of antihypertensive drugs are well known. Thus, bedtime, but not morning, dosing with cilnidipine significantly reduces nocturnal blood pressure. In addition, the dose-response curve, therapeutic coverage, and efficacy of the doxazosin gastrointestinal therapeutic system are all markedly dependent on the circadian time of drug administration. Moreover, valsartan administration at bedtime as opposed to upon awakening results in improved diurnal/nocturnal blood pressure ratio, such that the dosing time of valsartan can be chosen in relation to the dipper status of any given patient to improve therapeutic benefit and reduce cardiovascular risk.
SUMMARY: Nocturnal hypertension, which is characterized by the loss or even reversal of the expected 10-20% sleep-time blood-pressure decline, increases the risk of cardiac and cerebrovascular events. Chronotherapy provides a means of individualizing treatment of hypertension according to the circadian profile of blood pressure of each patient. The chronotherapeutic strategy constitutes a new option to optimize blood-pressure control and to reduce risk.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15300155     DOI: 10.1097/00041552-200409000-00004

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  9 in total

Review 1.  Chronotherapy improves blood pressure control and reduces vascular risk in CKD.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; Artemio Mojón; José R Fernández; Juan J Crespo; Ana Moyá; María T Ríos; Francesco Portaluppi
Journal:  Nat Rev Nephrol       Date:  2013-04-23       Impact factor: 28.314

2.  Diuretic drugs benefit patients with hypertension more with night-time dosing.

Authors:  Basil N Okeahialam; Esther N Ohihoin; Jayne Na Ajuluchukwu
Journal:  Ther Adv Drug Saf       Date:  2012-12

3.  Volume-associated ambulatory blood pressure patterns in hemodialysis patients.

Authors:  Rajiv Agarwal
Journal:  Hypertension       Date:  2009-06-15       Impact factor: 10.190

Review 4.  Evening versus morning dosing regimen drug therapy for hypertension.

Authors:  Ping Zhao; Ping Xu; Chaomin Wan; Zhengrong Wang
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

5.  Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRU.

Authors:  Shona Brothwell; Mary Dutton; Charles Ferro; Stephanie Stringer; Paul Cockwell
Journal:  BMC Nephrol       Date:  2013-10-10       Impact factor: 2.388

Review 6.  It's About Time: Advances in Understanding the Circadian Regulation of DNA Damage and Repair in Carcinogenesis and Cancer Treatment Outcomes.

Authors:  Prasanna V Ashok Kumar; Panshak P Dakup; Soumyadeep Sarkar; Jinita B Modasia; Madison S Motzner; Shobhan Gaddameedhi
Journal:  Yale J Biol Med       Date:  2019-06-27

7.  Optimal timing for antihypertensive dosing: focus on valsartan.

Authors:  Ramón C Hermida; Diana E Ayala; Carlos Calvo
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

Review 8.  Disruption of Circadian Rhythm Genes in Obstructive Sleep Apnea Patients-Possible Mechanisms Involved and Clinical Implication.

Authors:  Agata Gabryelska; Szymon Turkiewicz; Filip Franciszek Karuga; Marcin Sochal; Dominik Strzelecki; Piotr Białasiewicz
Journal:  Int J Mol Sci       Date:  2022-01-10       Impact factor: 5.923

9.  Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension.

Authors:  Nicola Di Trani; Hsuan-Chen Liu; Ruogu Qi; Dixita I Viswanath; Xuewu Liu; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Nanomedicine       Date:  2021-06-22       Impact factor: 6.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.